Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.

Timeline

Start

2019-01-18

Primary completion

2019-05-01

Completion

2019-05-01

Outcome

Outcome not reported

Stopped: “Study terminated due to a safety event which rendered the risk-benefit profile in NASH to no longer be adequately favorable”

Drugs

Indications